Evidence map›Paper›PMID 33275394›Full record

ArticleClinical orthopaedics and related research2020

Is Use of BMP-2 Associated with Tumor Growth and Osteoblastic Differentiation in Murine Models of Osteosarcoma?

Joseph K Kendal, Arvind Singla, Asmaa Affan, Kurt Hildebrand, Abdullah Al-Ani, Mark Ungrin, Douglas J Mahoney, Doha Itani, Frank R Jirik, Michael J Monument

Open access · greenAbstract read
In one paragraph

Article in Clinical orthopaedics and related research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Recombinant bone morphogenetic protein-2 attenuates colorectal cancer progression by orchestrating Hippo pathway activation, Yes-associated protein inhibition, and epithelial-mesenchymal transition suppression.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Joseph K KendalJ. K. Kendal, M. J. Monument, Section of Orthopaedic Surgery, Department of Surgery, University of Calgary, Calgary, Canada.
Arvind SinglaJ. K. Kendal, A. Singla, A. Affan, K. Hildebrand, A. Al-Ani, M. Ungrin, F. R. Jirik, M. J. Monument, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.
Asmaa AffanJ. K. Kendal, A. Singla, A. Affan, K. Hildebrand, A. Al-Ani, M. Ungrin, F. R. Jirik, M. J. Monument, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.
Kurt HildebrandJ. K. Kendal, A. Singla, A. Affan, K. Hildebrand, A. Al-Ani, M. Ungrin, F. R. Jirik, M. J. Monument, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.
Abdullah Al-AniJ. K. Kendal, A. Singla, A. Affan, K. Hildebrand, A. Al-Ani, M. Ungrin, F. R. Jirik, M. J. Monument, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.
Mark UngrinJ. K. Kendal, A. Singla, A. Affan, K. Hildebrand, A. Al-Ani, M. Ungrin, F. R. Jirik, M. J. Monument, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.
Douglas J MahoneyJ. K. Kendal, A. Singla, D. J. Mahoney, M. J. Monument, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Doha ItaniD. Itani, Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.
Frank R JirikJ. K. Kendal, A. Singla, A. Affan, K. Hildebrand, A. Al-Ani, M. Ungrin, F. R. Jirik, M. J. Monument, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.
Michael J MonumentJ. K. Kendal, M. J. Monument, Section of Orthopaedic Surgery, Department of Surgery, University of Calgary, Calgary, Canada.
Alberta Bone and Joint Health Institute · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe putative benefit of rhBMP-2 is in the setting of limb reconstruction using structural allografts, whether it be allograft-prosthetic composites, osteoarticular allografts, or intercalary segmental grafts. There are also potential advantages in augmenting osseointegration of uncemented endoprosthetics and in reducing infection. Recombinant human BMP-2 might mitigate nonunion in structural allograft augmented osteosarcoma limb salvage surgery; however, its use is limited because of concerns about the prooncogenic effects of the agent. QUESTIONS/PURPOSES: (1) To assess if BMP-2 signaling influences osteosarcoma cell line growth. (2) To characterize degree of osteosarcoma cell line osteoblastic differentiation in response to BMP-2. (3) To assess if BMP-2 signaling has a consistent effect on local or systemic tumor burden in various orthotopic murine models of osteosarcoma.

methodsIn this study, 143b, SaOS-2 and DLM8-M1 osteosarcoma cell lines were transfected with BMP-2 cDNA controlled by a constitutive promoter (experimental) or an empty vector (control) using a PiggyBac transposon system. Cellular proliferation was assessed using a quantitative MTT colorimetric assay. Osteoblastic differentiation was compared between control and experimental cell lines using quantitative real-time polymerase chain reaction of the osteoblastic markers connective tissue growth factor, Runx-2, Osterix, alkaline phosphatase and osteocalcin. Experimental and control cell lines were injected into the proximal tibia of either NOD-SCID (143b and SaOS-2 xenograft model), or C3H (DLM8-M1 syngeneic model) mice. Local tumor burden was quantitatively assessed using tumor volume caliper measurements and bioluminescence, and qualitatively assessed using post-mortem ex vivo microCT. Lung metastasis was qualitatively assessed by the presence of bioluminescence, and incidence was confirmed using histology. rhBMP-2 soaked absorbable collagen sponges (experimental) and sterile-H2O soaked absorbable collagen sponges (control) were implanted adjacent to 143b proximal tibial cell line injections to compare the effects of exogenous BMP-2 application with endogenous upregulation.

resultsConstitutive expression of BMP-2 increased the in vitro proliferation of 143b cells (absorbance values 1.2 ± 0.1 versus 0.89 ± 0.1, mean difference 0.36 [95% CI 0.12 to 0.6]; p = 0.01), but had no effect on SaOS-2 and DLM8-M1 cell proliferation. In response to constitutive BMP-2 expression, 143b cells had no differences in osteoblastic differentiation, while DLM8-M1 cells downregulated the early marker connective tissue growth factor (mean ΔCt 0.2 ± 0.1 versus 0.6 ± 0.1; p = 0.002) and upregulated the early-mid range marker Runx-2 (mean ΔCt -0.8 ± 0.1 versus -1.1 ± 0.1; p = 0.002), and SaOS-2 cells upregulated the mid-range marker Osterix (mean ΔCt -2.1 ± 0.6 versus -3.9 ± 0.6; p = 0.002). Constitutive expression of BMP-2 resulted in greater 143b and DLM8-M1 local tumor volume (143b: 307.2 ± 106.8 mm versus 1316 ± 387.4 mm, mean difference 1009 mm [95% CI 674.5 to 1343]; p < 0.001, DLM8-M1 week four: 0 mm versus 326.1 ± 72.8 mm, mean difference 326.1 mm [95% CI 121.2 to 531]; p = 0.009), but modestly reduced local tumor growth in SaOS-2 (9.5 x 10 ± 8.3x10 photons/s versus 9.3 x 10 ± 1.5 x 10 photons/s, mean difference 8.6 x 10 photons/s [95% CI 5.1 x 10 to 1.2 x 10]; p < 0.001). Application of exogenous rhBMP-2 also increased 143b local tumor volume (495 ± 91.9 mm versus 1335 ± 102.7 mm, mean difference 840.3 mm [95% CI 671.7 to 1009]; p < 0.001). Incidence of lung metastases was not different between experimental or control groups for all experimental conditions.

conclusionsAs demonstrated by others, ectopic BMP-2 signaling has unpredictable effects on local tumor proliferation in murine models of osteosarcoma and does not consistently result in osteosarcoma cell line differentiation. Further investigations into other methods of safe bone and soft tissue healing augmentation and the use of differentiation therapies is warranted. CLINICAL RELEVANCE: Our results indicate that BMP-2 has the potential to stimulate the growth of osteosarcoma cells that are poorly responsive to BMP-2 mediated osteoblastic differentiation. As this differentiation potential is unpredictable in the clinical setting, BMP-2 may promote the growth of microscopic residual tumor burden after resection. Our study provides further support for the recommendation to avoid the use of BMP-2 after limb-salvage surgery in patients with osteosarcoma.

Indexed as

Cell DifferentiationCell ProliferationAdolescentAnimalsBone Morphogenetic Protein 2Bone NeoplasmsCell Line, TumorCell MovementChildFemaleGene Expression Regulation, NeoplasticHumansMaleMice, Inbred C3HMice, Inbred NODMice, SCIDBMP2 protein, humanBone Morphogenetic Protein 2

Identifiers

PMID33275394
PMCPMC7899403
OpenAlexW3049537661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.